

# James H Maccabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5627910/publications.pdf>

Version: 2024-02-01

227  
papers

10,853  
citations

50170

46  
h-index

42291

92  
g-index

253  
all docs

253  
docs citations

253  
times ranked

12809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. <i>Nature Genetics</i> , 2018, 50, 381-389.	9.4	1,332
2	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	4.0	685
3	Preterm Birth and Psychiatric Disorders in Young Adult Life. <i>Archives of General Psychiatry</i> , 2012, 69, E1-8.	13.8	388
4	Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users. <i>Schizophrenia Bulletin</i> , 2014, 40, 1509-1517.	2.3	364
5	Antipsychotic medication in schizophrenia: a review. <i>British Medical Bulletin</i> , 2015, 114, 169-179.	2.7	356
6	Excellent school performance at age 16 and risk of adult bipolar disorder: national cohort study. <i>British Journal of Psychiatry</i> , 2010, 196, 109-115.	1.7	294
7	Fecundity of Patients With Schizophrenia, Autism, Bipolar Disorder, Depression, Anorexia Nervosa, or Substance Abuse vs Their Unaffected Siblings. <i>JAMA Psychiatry</i> , 2013, 70, 22.	6.0	284
8	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
9	Does tobacco use cause psychosis? Systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2015, 2, 718-725.	3.7	240
10	Advancing Maternal Age Is Associated With Increasing Risk for Autism: A Review and Meta-Analysis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2012, 51, 477-486.e1.	0.3	233
11	Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder. <i>British Journal of Psychiatry</i> , 2005, 186, 369-377.	1.7	206
12	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. <i>Psychological Medicine</i> , 2016, 46, 3231-3240.	2.7	202
13	Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. <i>Psychological Medicine</i> , 2017, 47, 1981-1989.	2.7	200
14	Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. <i>BMC Psychiatry</i> , 2017, 17, 12.	1.1	170
15	How Genes and Environmental Factors Determine the Different Neurodevelopmental Trajectories of Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2012, 38, 209-214.	2.3	161
16	Gender difference in age at onset of schizophrenia: a meta-analysis. <i>Psychological Medicine</i> , 2013, 43, 155-167.	2.7	136
17	Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2016, 171, 215-224.	1.1	130
18	A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 98-106.	2.2	121

#	ARTICLE	IF	CITATIONS
19	Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 963.	6.0	118
20	Maternal Smoking During Pregnancy and School Performance at Age 15. <i>Epidemiology</i> , 2006, 17, 524-530.	1.2	109
21	Scholastic achievement at age 16 and risk of schizophrenia and other psychoses: a national cohort study. <i>Psychological Medicine</i> , 2008, 38, 1133-1140.	2.7	106
22	Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 990-998.	4.0	106
23	Do premorbid and post-onset cognitive functioning differ between schizophrenia and bipolar disorder? A systematic review and meta-analysis. <i>Psychological Medicine</i> , 2015, 45, 381-394.	2.7	105
24	Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. <i>Lancet Psychiatry</i> , 2016, 3, 358-366.	3.7	105
25	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 222-223.	1.4	102
26	Reasons for discontinuing clozapine: A cohort study of patients commencing treatment. <i>Schizophrenia Research</i> , 2016, 174, 113-119.	1.1	100
27	Decline in Cognitive Performance Between Ages 13 and 18 Years and the Risk for Psychosis in Adulthood. <i>JAMA Psychiatry</i> , 2013, 70, 261.	6.0	99
28	Is there a link between childhood trauma, cognition, and amygdala and hippocampus volume in first-episode psychosis?. <i>Schizophrenia Research</i> , 2012, 137, 73-79.	1.1	96
29	Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 863.	1.8	85
30	Sleep and Circadian Rhythm Disturbance in Remitted Schizophrenia and Bipolar Disorder: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1126-1143.	2.3	83
31	Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2022, 220, 115-120.	1.7	81
32	Cannabis use, gender and age of onset of schizophrenia: Data from the A+SOP study. <i>Psychiatry Research</i> , 2014, 215, 528-532.	1.7	80
33	Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, 1064-1069.	2.3	76
34	Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. <i>Molecular Psychiatry</i> , 2017, 22, 1502-1508.	4.1	75
35	High educational performance is a distinctive feature of bipolar disorder: a study on cognition in bipolar disorder, schizophrenia patients, relatives and controls. <i>Psychological Medicine</i> , 2016, 46, 807-818.	2.7	74
36	Clozapine treatment and risk of COVID-19 infection: retrospective cohort study. <i>British Journal of Psychiatry</i> , 2021, 219, 368-374.	1.7	72

#	ARTICLE	IF	CITATIONS
37	DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. <i>ELife</i> , 2021, 10, .	2.8	72
38	Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. <i>Psychological Medicine</i> , 2014, 44, 1625-1637.	2.7	65
39	Duration of untreated psychosis and ethnicity in the Å†SOP first-onset psychosis study. <i>Psychological Medicine</i> , 2006, 36, 239-247.	2.7	64
40	Population-based Cohort Studies on Premorbid Cognitive Function in Schizophrenia. <i>Epidemiologic Reviews</i> , 2008, 30, 77-83.	1.3	62
41	Adverse pregnancy outcomes in mothers with affective psychosis. <i>Bipolar Disorders</i> , 2007, 9, 305-309.	1.1	60
42	Clozapine-induced agranulocytosis. <i>Annals of Hematology</i> , 2020, 99, 2477-2482.	0.8	58
43	Substance use, medication adherence and outcome one year following a first episode of psychosis. <i>Schizophrenia Research</i> , 2016, 170, 311-317.	1.1	55
44	Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism. <i>American Journal of Psychiatry</i> , 2019, 176, 477-486.	4.0	54
45	Lifetime reproductive output over two generations in patients with psychosis and their unaffected siblings: the Uppsala 1915â€“1929 Birth Cohort Multigenerational Study. <i>Psychological Medicine</i> , 2009, 39, 1667.	2.7	53
46	Only a small proportion of patients with first episode psychosis come via prodromal services: a retrospective survey of a large UK mental health programme. <i>BMC Psychiatry</i> , 2017, 17, 308.	1.1	53
47	The relationship between nicotine and psychosis. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531985996.	1.2	52
48	Clozapine and allâ€“cause mortality in treatmentâ€“resistant schizophrenia: a historical cohort study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 237-247.	2.2	51
49	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). <i>Schizophrenia Bulletin</i> , 2021, 47, 505-516.	2.3	51
50	Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. <i>Molecular Psychiatry</i> , 2016, 21, 903-909.	4.1	50
51	Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure. <i>Schizophrenia Bulletin</i> , 2019, 45, 69-79.	2.3	47
52	Superior intellectual ability in schizophrenia: Neuropsychological characteristics.. <i>Neuropsychology</i> , 2012, 26, 181-190.	1.0	46
53	Capturing Rest-Activity Profiles in Schizophrenia Using Wearable and Mobile Technologies: Development, Implementation, Feasibility, and Acceptability of a Remote Monitoring Platform. <i>JMIR MHealth and UHealth</i> , 2018, 6, e188.	1.8	46
54	Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. <i>BMC Psychiatry</i> , 2015, 15, 166.	1.1	45

#	ARTICLE	IF	CITATIONS
55	Academic achievement and schizophrenia: a systematic meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 1949-1965.	2.7	45
56	Optimizing Outcomes in Clozapine Rechallenge Following Neutropenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1410-e1416.	1.1	44
57	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	6.0	44
58	Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults. <i>Psychological Medicine</i> , 2013, 43, 2393-2401.	2.7	43
59	A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. <i>Molecular Psychiatry</i> , 2019, 24, 328-337.	4.1	42
60	Biological Predictors of Clozapine Response: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 327.	1.3	41
61	Is there an association between the COMT gene and P300 endophenotypes?. <i>European Psychiatry</i> , 2006, 21, 70-73.	0.1	40
62	Clozapine use in childhood and adolescent schizophrenia: A nationwide population-based study. <i>European Neuropsychopharmacology</i> , 2015, 25, 857-863.	0.3	40
63	The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1233-e1241.	1.1	39
64	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 662-671.	2.3	39
65	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 427-438.	2.2	38
66	Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. <i>Psychological Medicine</i> , 2021, 51, 44-53.	2.7	38
67	Epigenetics, genomic mutations and cognitive function. <i>Cognitive Neuropsychiatry</i> , 2009, 14, 377-390.	0.7	36
68	Specificity of the jumpâ€œconclusions bias in deluded patients. <i>British Journal of Clinical Psychology</i> , 2008, 47, 239-244.	1.7	35
69	Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. <i>BMC Psychiatry</i> , 2016, 16, 441.	1.1	35
70	Artistic creativity and risk for schizophrenia, bipolar disorder and unipolar depression: a Swedish population-based caseâ€œcontrol study and sib-pair analysis. <i>British Journal of Psychiatry</i> , 2018, 212, 370-376.	1.7	34
71	Management of clozapine treatment during the COVID-19 pandemic. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532092816.	1.2	34
72	Educational achievement in psychiatric patients and their siblings: a register-based study in 30 000 individuals in The Netherlands. <i>Psychological Medicine</i> , 2017, 47, 776-784.	2.7	33

#	ARTICLE	IF	CITATIONS
73	The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 600-604.	0.7	33
74	Sodium valproate and clozapine induced neutropenia: A case control study using register data. <i>Schizophrenia Research</i> , 2018, 195, 267-273.	1.1	32
75	A systematic review and meta-analysis of mental health service use in people who report psychotic experiences. <i>Microbial Biotechnology</i> , 2018, 12, 275-285.	0.9	30
76	Consensus statement on the use of clozapine during the COVID-19 pandemic. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 200061.	1.4	30
77	Antipsychotic polypharmacy prescribing and risk of hospital readmission. <i>Psychopharmacology</i> , 2018, 235, 281-289.	1.5	29
78	Peripheral immune markers and antipsychotic non-response in psychosis. <i>Schizophrenia Research</i> , 2021, 230, 1-8.	1.1	29
79	The side effect profile of Clozapine in real world data of three large mental health hospitals. <i>PLoS ONE</i> , 2020, 15, e0243437.	1.1	28
80	Change in cannabis use in the general population: A longitudinal study on the impact on psychotic experiences. <i>Schizophrenia Research</i> , 2014, 157, 266-270.	1.1	27
81	Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 441-446.	0.7	26
82	Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2017, 52, 1101-1111.	1.6	26
83	Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010. <i>Human Psychopharmacology</i> , 2012, 27, 277-283.	0.7	25
84	Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis. <i>British Journal of Psychiatry</i> , 2015, 206, 164-165.	1.7	25
85	Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 123-132.	2.2	25
86	Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare. <i>Schizophrenia Research</i> , 2016, 174, 106-112.	1.1	24
87	Subclinical psychotic experiences and subsequent contact with mental health services. <i>BJPsych Open</i> , 2017, 3, 64-70.	0.3	24
88	Hepatitis, Interstitial Nephritis, and Pancreatitis in Association With Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 520-527.	0.7	24
89	Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. <i>Journal of Psychopharmacology</i> , 2019, 33, 449-458.	2.0	24
90	Psychiatric symptoms and risk of victimisation: a population-based study from Southeast London. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 168-178.	1.8	24

#	ARTICLE	IF	CITATIONS
91	There Is Life After the UK Clozapine Central Non-Rechallenge Database. <i>Schizophrenia Bulletin</i> , 2021, 47, 1088-1098.	2.3	24
92	Tobacco smoking is associated with psychotic experiences in the general population of South London. <i>Psychological Medicine</i> , 2018, 48, 123-131.	2.7	23
93	Pharmacoevidence research: delivering evidence about drug safety and effectiveness in mental health. <i>Lancet Psychiatry</i> , 2020, 7, 363-370.	3.7	23
94	Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. <i>NPJ Schizophrenia</i> , 2022, 8, 21.	2.0	23
95	Do schizophrenic patients who managed to get to university have a non-developmental form of illness?. <i>Psychological Medicine</i> , 2002, 32, 535-544.	2.7	22
96	Neuropsychological function at first episode in treatment-resistant psychosis: findings from the A†SOP-10 study. <i>Psychological Medicine</i> , 2019, 49, 2100-2110.	2.7	22
97	Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. <i>Pharmacogenomics Journal</i> , 2015, 15, 461-466.	0.9	21
98	Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 376-386.	2.7	21
99	Gene polymorphisms potentially related to the pharmacokinetics of clozapine. <i>International Clinical Psychopharmacology</i> , 2016, 31, 179-184.	0.9	20
100	Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 450-455.	0.7	20
101	Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 3045-3054.	1.5	20
102	The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. <i>Psychopharmacology</i> , 2019, 236, 1931-1935.	1.5	20
103	Childhood abuse and psychotic experiences – evidence for mediation by adulthood adverse life events. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 300-309.	1.8	20
104	Clozapine Rechallenge Following Clozapine-Induced Pericarditis. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 959-961.	1.1	20
105	Granulocyte Colony Stimulating Factor (G-CSF) can allow treatment with clozapine in a patient with severe Benign Ethnic Neutropaenia (BEN): a case report. <i>Journal of Psychopharmacology</i> , 2012, 26, 1280-1282.	2.0	19
106	Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. <i>Journal of Psychopharmacology</i> , 2016, 30, 436-443.	2.0	19
107	Schizophrenia polygenic risk predicts general cognitive deficit but not cognitive decline in healthy older adults. <i>Translational Psychiatry</i> , 2020, 10, 422.	2.4	19
108	Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation – Is It Feasible to Develop Evidence-Based Guidelines?. <i>Schizophrenia Bulletin</i> , 2022, 48, 176-189.	2.3	19

#	ARTICLE	IF	CITATIONS
109	Saccadic distractibility is elevated in schizophrenia patients, but not in their unaffected relatives. <i>Psychological Medicine</i> , 2005, 35, 1727-1736.	2.7	18
110	Eye tracking in schizophrenia: Does the antisaccade task measure anything that the smooth pursuit task does not?. <i>Psychiatry Research</i> , 2005, 136, 181-188.	1.7	18
111	Schizophrenia patients with high intelligence: A clinically distinct sub-type of schizophrenia?. <i>European Psychiatry</i> , 2015, 30, 628-632.	0.1	18
112	Inverse association between urbanicity and treatment resistance in schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 150-155.	1.1	18
113	Point-of-care measurement of clozapine concentration using a finger-stick blood sample. <i>Journal of Psychopharmacology</i> , 2021, 35, 279-283.	2.0	18
114	Feeling the pressure: work stress and mental health. <i>Psychological Medicine</i> , 2007, 37, 1073-1074.	2.7	17
115	Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model. <i>JAMA Network Open</i> , 2020, 3, e205888.	2.8	17
116	Psychotic experiences, psychiatric comorbidity and mental health need in the general population: a cross-sectional and cohort study in Southeast London. <i>Psychological Medicine</i> , 2021, 51, 147-157.	2.7	17
117	Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. <i>Schizophrenia Research</i> , 2021, 232, 68-76.	1.1	17
118	Behavior Therapy Attenuates Clozapine-Induced Obsessions and Compulsions. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 1179-1180.	1.1	17
119	Advancing paternal age and psychiatric disorders. <i>World Psychiatry</i> , 2015, 14, 91-93.	4.8	16
120	Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 496-502.	0.7	16
121	Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 294-297.	1.1	16
122	A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. <i>British Journal of Psychiatry</i> , 2020, 217, 506-513.	1.7	16
123	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy. <i>British Journal of Psychiatry</i> , 2021, 219, 644-651.	1.7	16
124	Intellectual functioning in schizophrenia: a marker of neurodevelopmental damage?. <i>Journal of Intellectual Disability Research</i> , 2004, 48, 519-523.	1.2	15
125	Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 117-122.	1.2	15
126	SleepSight. , 2016, , .		15



#	ARTICLE	IF	CITATIONS
127	Predictors of Nonhospitalization and Functional Response in Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 148-154.	0.7	15
128	Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland. <i>Nordic Journal of Psychiatry</i> , 2018, 72, 497-500.	0.7	15
129	Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis. <i>Psychological Medicine</i> , 2022, 52, 1-13.	2.7	14
130	Clozapine Response in Schizophrenia and Hematological Changes. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 19-24.	0.7	14
131	Neuropsychological correlates of eye movement abnormalities in schizophrenic patients and their unaffected relatives. <i>Psychiatry Research</i> , 2009, 168, 193-197.	1.7	13
132	Need to bleed? Clozapine haematological monitoring approaches a time for change. <i>International Clinical Psychopharmacology</i> , 2019, 34, 264-268.	0.9	13
133	Effect of age on the relative efficacy of clozapine in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 109-120.	2.2	13
134	Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. <i>Lancet Psychiatry</i> , 2022, 9, 636-644.	3.7	13
135	The relationship between eye movement and brain structural abnormalities in patients with schizophrenia and their unaffected relatives. <i>Journal of Psychiatric Research</i> , 2006, 40, 589-598.	1.5	12
136	Cannabis Use is a Better Indicator of Poor Mental Health in Women Than in Men: A Cross-Sectional Study in Young Adults from the General Population. <i>Community Mental Health Journal</i> , 2014, 50, 823-830.	1.1	12
137	The aetiology of schizophrenia: what have the Swedish Medical Registers taught us?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 1471-1479.	1.6	12
138	Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 79-83.	1.2	12
139	Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?. <i>European Journal of Health Economics</i> , 2019, 20, 1425-1435.	1.4	12
140	Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden. <i>Schizophrenia Bulletin</i> , 2019, 46, 303-310.	2.3	12
141	Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine. <i>Pharmacogenomics</i> , 2013, 14, 1907-1914.	0.6	11
142	Making clozapine safer: current perspectives on improving its tolerability. <i>Future Neurology</i> , 2014, 9, 313-322.	0.9	11
143	Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. <i>British Journal of Psychiatry</i> , 2021, 218, 224-229.	1.7	11
144	Clozapine-induced obsessive-compulsive symptoms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 1209.	2.5	10

#	ARTICLE	IF	CITATIONS
145	It is time to start taking tobacco seriously as a risk factor for psychosis: self-medication cannot explain the association. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 3-4.	2.2	10
146	Clozapine Rechallenge Following Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 372-379.	0.7	10
147	Sudden-Onset Catatonia Following Clozapine Withdrawal. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e899-e899.	1.1	10
148	Delayed school progression and mental health problems in adolescence: a population-based study in 10,803 adolescents. <i>BMC Psychiatry</i> , 2014, 14, 244.	1.1	9
149	Pharmacological interventions for clozapine-induced sinus tachycardia. <i>The Cochrane Library</i> , 2016, 2016, CD011566.	1.5	9
150	Personalised approaches to pharmacotherapy for schizophrenia. <i>BJ Psych Advances</i> , 2016, 22, 78-86.	0.5	9
151	Educational Level, Underachievement, and General Mental Health Problems in 10,866 Adolescents. <i>Academic Pediatrics</i> , 2017, 17, 642-648.	1.0	9
152	Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. <i>Psychopharmacology</i> , 2020, 237, 443-451.	1.5	9
153	Augmentation of clozapine with ECT: a retrospective case analysis. <i>Acta Neuropsychiatrica</i> , 2021, 33, 31-36.	1.0	9
154	Hyoscine for clozapine-induced hypersalivation. <i>International Clinical Psychopharmacology</i> , 2019, 34, 101-107.	0.9	8
155	The temporal dynamics of sleep disturbance and psychopathology in psychosis: a digital sampling study. <i>Psychological Medicine</i> , 2022, 52, 2741-2750.	2.7	8
156	Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration. <i>Psychiatry Research</i> , 2021, 305, 114211.	1.7	8
157	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 193, 391-398.	1.1	7
158	The association of migration and ethnicity with use of the Improving Access to Psychological Treatment (IAPT) programme: a general population cohort study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 1943-1956.	1.6	7
159	Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2022, 57, 1341-1355.	1.6	7
160	Service users' and carers' views on research towards stratified medicine in psychiatry: a qualitative study. <i>BMC Research Notes</i> , 2015, 8, 489.	0.6	6
161	The association between neighbourhood characteristics and physical victimisation in men and women with mental disorders. <i>BJPsych Open</i> , 2020, 6, e73.	0.3	6
162	Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study. <i>BJPsych Open</i> , 2020, 6, e82.	0.3	6

#	ARTICLE	IF	CITATIONS
163	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093790.	1.2	6
164	A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway. <i>Pharmacoeconomics</i> , 2020, 38, 537-555.	1.7	6
165	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. <i>European Neuropsychopharmacology</i> , 2021, 47, 130-135.	0.3	6
166	Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia. <i>Schizophrenia Research</i> , 2021, 235, 102-108.	1.1	6
167	Real-World Outcomes in the Management of Refractory Psychosis. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	6
168	Clozapine treatment and risk of severe COVID-19 infection. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 79-85.	2.2	6
169	Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 13.	2.0	6
170	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. <i>British Journal of Psychiatry</i> , 2022, 221, 740-747.	1.7	6
171	Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110371.	1.2	5
172	Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine. <i>Journal of Psychopharmacology</i> , 2022, 36, 498-506.	2.0	5
173	Paradoxes in creativity and psychiatric conditions. , 0, , 289-300.		4
174	Pre-morbid fertility in psychosis: Findings from the AESOP first episode study. <i>Schizophrenia Research</i> , 2014, 156, 168-173.	1.1	4
175	P029 Sleep and circadian rhythm disturbances and relapse in schizophrenia: a digital phenotyping study. , 2019, , .		4
176	COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine. <i>European Neuropsychopharmacology</i> , 2022, 56, 92-99.	0.3	4
177	Psychiatry in Cambodia: the phoenix rises from the ashes. <i>International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists</i> , 2007, 4, 37-38.	0.2	3
178	Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532211033.	1.2	3
179	Tobacco and psychosis: Not quite a smoking gun. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 859-860.	1.3	2
180	41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?. <i>Schizophrenia Bulletin</i> , 2018, 44, S67-S67.	2.3	2

#	ARTICLE	IF	CITATIONS
181	T74. ACADEMIC ACHIEVEMENT AND SCHIZOPHRENIA: A META-ANALYSIS. Schizophrenia Bulletin, 2018, 44, S143-S143.	2.3	2
182	Clozapine: Gold Standard Treatment for Refractory Schizophrenia: Now or Never?. , 2014, , 81-91.		2
183	Clozapine Treatment and Risk of COVID-19. SSRN Electronic Journal, 0, , .	0.4	2
184	Psychiatry in Cambodia: the phoenix rises from the ashes. International Psychiatry: Bulletin of the Board of International Affairs of the Royal College of Psychiatrists, 2007, 4, 37-38.	0.2	2
185	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. BMJ Open, 2021, 11, e054160.	0.8	2
186	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM. British Journal of Psychiatry, 2021, 219, 695-695.	1.7	2
187	Clinical Handbook of Schizophrenia. Edited by Kim T. Mueser & Dilip V. Jeste, Guilford Press. 2008. US\$75.00 (hb). 650pp. ISBN: 9781593856526. British Journal of Psychiatry, 2009, 195, 89-89.	1.7	1
188	Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia. Evidence-Based Mental Health, 2010, 13, 57-57.	2.2	1
189	Poster #4 SEX DIFFERENCES IN PLASMA CLOZAPINE/NORCLOZAPINE AND OLANZAPINE CONCENTRATIONS IN CLINICAL PRACTICE: DATA FROM A THERAPEUTIC DRUG MONITORING SERVICE. Schizophrenia Research, 2012, 136, S186.	1.1	1
190	SYSTEMATIC REVIEW AND META-ANALYSIS ON ASSOCIATIONS BETWEEN TOBACCO SMOKING AND BOTH THE DIAGNOSIS AND THE CLINICAL SYMPTOMS OF PSYCHOSIS?. Schizophrenia Research, 2014, 153, S8.	1.1	1
191	SU95. The Importance and Challenges of Longitudinal Studies Among Patients Diagnosed With Schizophrenia: Predicting Response to Antipsychotic Medication Using Strata. Schizophrenia Bulletin, 2017, 43, S195-S195.	2.3	1
192	Longitudinal Epigenetic Analysis Of Clozapine Use In Treatment-Resistant Schizophrenia: Data From The Crestar Consortium. European Neuropsychopharmacology, 2017, 27, S463-S464.	0.3	1
193	SU116. Longitudinal Epigenetic Analysis of Clozapine Use in Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 2017, 43, S203-S203.	2.3	1
194	33. Clinical Predictors of 2 Types of Treatment Resistance in Patients With Psychosis. Schizophrenia Bulletin, 2017, 43, S20-S20.	2.3	1
195	Editors' Note: Paper Selected for the Mitchell B. Balter Award 2017. Journal of Clinical Psychopharmacology, 2018, 38, 316-316.	0.7	1
196	T66. PREDICTING TREATMENT RESISTANT SCHIZOPHRENIA AT FIRST-EPISODE OF PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S229-S230.	2.3	1
197	S62. COGNITIVE DEFICITS IN TREATMENT RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S56-S57.	2.3	1
198	Clozapine and COVID-19: The authors respond. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E2.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Investigating Patient Acceptability of Stratified Medicine for Schizophrenia: A Mixed Methods Study. Schizophrenia Bulletin Open, 2021, 2, sgab016.	0.9	1
200	Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit. Journal of Psychopharmacology, 0, , 026988112211040.	2.0	1
201	Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. , 2022, 8, .		1
202	Pregnancy outcomes of mothers with bipolar disorders. Journal of Affective Disorders, 2008, 107, S25.	2.0	0
203	Review: premorbid IQ is inversely associated with future risk of schizophrenia. Evidence-Based Mental Health, 2012, 15, 33-33.	2.2	0
204	Schizophrenia, <i>3rd edn</i>. Edited by D. R. Weinberger and P. J. Harrison. (Pp. 736; Â£131.00; ISBN:) Tj ETQq0 0,0 rgBT /Oerlock 10	2.7	0
205	Poster #93 CARDIOVASCULAR DRUG USE IN PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER. Schizophrenia Research, 2012, 136, S219.	1.1	0
206	CIGARETTE SMOKING IS EQUALLY STRONGLY ASSOCIATED WITH PSYCHOTIC-LIKE EXPERIENCES AS CANNABIS USE. Schizophrenia Research, 2014, 153, S9.	1.1	0
207	COGNITIVE TRAJECTORY BETWEEN AGES 10, 13 AND 18 AND RISK FOR PSYCHOSIS IN ADULTHOOD: A SWEDISH LONGITUDINAL COHORT STUDY. Schizophrenia Research, 2014, 153, S81.	1.1	0
208	Tobacco use and psychosis: missing the risk of bias assessment and other methodological considerations â€œ Authors' reply. Lancet Psychiatry,the, 2015, 2, 865-866.	3.7	0
209	27. Cannabis and Stimulant Misuse Do Not Completely Confound the Association Between Cigarette Smoking and Psychotic Experiences in Southeast London. Schizophrenia Bulletin, 2017, 43, S17-S18.	2.3	0
210	41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S66-S66.	2.3	0
211	S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S382-S382.	2.3	0
212	O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S81-S82.	2.3	0
213	THE IMPACT OF THE DUFFY-NULL GENOTYPE IN CLOZAPINE-ASSOCIATED NEUTROPENIA: A GENOME-WIDE ASSOCIATION STUDY IN INDIVIDUALS OF AFRICAN ANCESTRY. European Neuropsychopharmacology, 2019, 29, S1031.	0.3	0
214	6.3 DOES TOBACCO SMOKING CAUSE PSYCHOSIS?. Schizophrenia Bulletin, 2019, 45, S96-S96.	2.3	0
215	39â€œ...The immunomodulatory effect of clozapine in patients with treatment resistant schizophrenia: a retrospective cohort study. , 2019, , .		0
216	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S238-S238.	2.3	0

#	ARTICLE	IF	CITATIONS
217	M2.12. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S217-S217.	2.3	0
218	Should Patients' Values Be Discussed in Relation to Long-Term Blood Monitoring Before and During Clozapine Treatment?. Journal of Clinical Psychopharmacology, 2020, 40, 409-410.	0.7	0
219	P.118 Longitudinal DNA methylation changes associated with improvement of psychotic symptoms during clozapine treatment. European Neuropsychopharmacology, 2020, 31, S13-S14.	0.3	0
220	Seeing is believing. Acta Psychiatrica Scandinavica, 2021, 144, 3-5.	2.2	0
221	¿Hay una asociación entre el gen de la COMT y los endofenotipos de la esquizofrenia? (Ed Española), 2006, 13, 244-248.	0.0	0
222	Good financial management does not lead to better services. BMJ: British Medical Journal, 2006, 333, 920.1.	2.4	0
223	Epidemiology, impact, and predictors of treatment-resistant schizophrenia. , 2018, , .		0
224	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
225	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
226	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0
227	The side effect profile of Clozapine in real world data of three large mental health hospitals. , 2020, 15, e0243437.		0